Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis

Uterine Fibroids Clinical Trial

Official title:

Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03500367
• Other study ID #: LPMS201802
• Status: Recruiting
• Phase: Phase 4
• First received: March 10, 2018
• Last updated: April 14, 2018
• Start date: January 1, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: April 2018
• Source: Peking Union Medical College Hospital
• Contact: Fengzh Feng, MD
• Phone: 18612671869
• Email: fengfzh[@]pumch.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective non-randomized open label clinical trial to research the efficacy and safety of sirolimus in patients with symptomatic, recurrent uterine fibroids or/and various rare leiomyoma.

Description:

Recent studies indicate that mTOR pathway is a specific and sensitive tumor target molecule in uterine fibroids, which can be used as a target molecule for interventional therapy and can provide a new cut-in point for nonoperative treatment. However, the application of mTOR inhibitor (sirolimus) in the treatment of uterine fibroids remains blank. Our study was designed as a prospective non-randomized open label clinical trial to research its efficacy and safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria

1. Patients who suffer from menorrhagia and pressure symptoms and whose pelvic ultrasound or pelvic MRI indicates uterine fibroids; or who has underwent myomectomy but suffer from menorrhagia and pressure symptoms again with pelvic ultrasound or pelvic MRI indicating uterine fibroids; or whose other imageological examinations or established surgical diagnosis indicate various rare types of myomatosis and who expect a drug therapy.

2. Symptoms of uterine fibroids can be confirmed if one or multiple symptoms below exist:

• MP shows an excessive amount of bleeding during menstruation (>80.0 mL)

• A subject report shows three excessive amounts of bleeding during menstruation in latest six months

• A subject report indicates pelvic pressure symptoms/pain that are likely related to uterine fibroids.

3. According to results of medical history, physical examinations, gynecological examinations and laboratory examinations, patients are in a good overall condition (except uterine fibroids).

4. Cervical smears show a normal result or have no clinical significance, where further follow-up is unnecessary. If there's a normal result in the latest six month in the medical record of a subject, the subject can pass the inspection of cervical smears. A HPV test can be applied to subjects with equivocal ASCUS as an auxiliary test. ASCUS subjects who get a negative result of a HPV test can be included into this study.

5. Endometrial biopsy should be conducted to eliminate non-endometrial lesions if necessary.

6. Subjects didn't receive any drug therapy for uterine fibroids three months before the clinical test.

7. Female adults have menstruation (>18 years old) and are not during pregnancy and lactation.

8. Subjects have good organ function and results of their biochemical examinations meet the following conditions:

• AST=2.5×the upper limit of normal (ULN),

• ALT=2.5×the upper limit of normal (ULN),

• Serum total bilirubin=1.5×the upper limit of normal (ULN),

• Creatinine=1.5×the upper limit of normal (ULN).

9. Patients have signed the informed consent.

Exclusion Criteria

1. Patients are in a period of pregnancy and lactation (patients delivered, miscarried or breast-feed in three months before the treatment)

2. Patients are allergic to any ingredient of the medicine

3. Patients suffer from a disease requiring immediate blood transfusion

4. Patients suffer from a disease that may impact implementation of the study or explanation of results. This type of diseases includes:

• Known severe blood coagulation disorders

• Known anemia that is not caused by HMB

• Known hemoglobinopathy

• Patients suffered or suffer from cancer of the uterus, cervical carcinoma, ovarian cancer or breast cancer 5) An ultrasonic examination shows one or multiple ovarian cysts with a diameter >30 mm 6) Ovarian tumors or pelvic mass of unknown origin 7) Known or suspected endometrial polyp >15 mm

5. Alcohol or drug (such as aperient) abuse

6. Undiagnosed abnormal bleeding of the reproductive system.

7. Patients also participate in another clinical medicine study

8. Patients took part in another clinical trial that may influence this study before this study

Related Conditions & MeSH terms

• Leiomyoma
• Leiomyomatosis
• Uterine Fibroids

Intervention

Drug:
• rapamycin
rapamycin, 2 mg a day, orally ,for 3months

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences	Beijing	China/Beiing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Fritsch M, Schmidt N, Gröticke I, Frisk AL, Keator CS, Koch M, Slayden OD. Application of a Patient Derived Xenograft Model for Predicative Study of Uterine Fibroid Disease. PLoS One. 2015 Nov 20;10(11):e0142429. doi: 10.1371/journal.pone.0142429. eCollection 2015. — View Citation

Kashani BN, Centini G, Morelli SS, Weiss G, Petraglia F. Role of Medical Management for Uterine Leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:85-103. doi: 10.1016/j.bpobgyn.2015.11.016. Epub 2015 Nov 25. Review. — View Citation

Prizant H, Hammes SR. Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer. Endocrinology. 2016 Sep;157(9):3374-83. doi: 10.1210/en.2016-1395. Epub 2016 Jul 13. Review. — View Citation

Prizant H, Sen A, Light A, Cho SN, DeMayo FJ, Lydon JP, Hammes SR. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. Mol Endocrinol. 2013 Sep;27(9):1403-14. doi: 10.1210/me.2013-1059. Epub 2013 Jul 2. — View Citation

Suo G, Sadarangani A, Tang W, Cowan BD, Wang JY. Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells. Reprod Sci. 2014 Sep;21(9):1161-70. doi: 10.1177/1933719114532839. Epub 2014 Apr 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	size of uterus and the myoma	efficacy assessment	2 day
Secondary	hormone levels	ovarian function assessment	2 day
Secondary	menstrual blood volume / haemorrhage	symptom assessment	1 day
Secondary	adverse event	safety assessment	2 day
Secondary	follicular size	safety assessment	2 day

External Links

•   Lymphangioleiomyomatosis (LAM)
•   Medical Management for Uterine Leiomyomas
•   Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells
•   Uterine-Specific Loss of Tsc2 Leads to Myometrial Tumors in Both the Uterus and Lungs
•   Xenograft Model for Predicative Study of Uterine Fibroid Disease